420 related articles for article (PubMed ID: 33476723)
1. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ghoneum A; Almousa S; Warren B; Abdulfattah AY; Shu J; Abouelfadl H; Gonzalez D; Livingston C; Said N
Semin Cancer Biol; 2021 Dec; 77():83-98. PubMed ID: 33476723
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumour microenvironment in platinum-resistant ovarian cancer.
Cummings M; Freer C; Orsi NM
Semin Cancer Biol; 2021 Dec; 77():3-28. PubMed ID: 33607246
[TBL] [Abstract][Full Text] [Related]
3. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets.
da Costa AABA; Baiocchi G
Semin Cancer Biol; 2021 Dec; 77():29-41. PubMed ID: 33161141
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
7. Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway.
Ghoneum A; Gonzalez D; Afify H; Shu J; Hegarty A; Adisa J; Kelly M; Lentz S; Salsbury F; Said N
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291886
[TBL] [Abstract][Full Text] [Related]
8. New approaches for targeting platinum-resistant ovarian cancer.
McMullen M; Madariaga A; Lheureux S
Semin Cancer Biol; 2021 Dec; 77():167-181. PubMed ID: 32871277
[TBL] [Abstract][Full Text] [Related]
9. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.
Zou X; Zhao Y; Liang X; Wang H; Zhu Y; Shao Q
Front Immunol; 2021; 12():641937. PubMed ID: 33868274
[TBL] [Abstract][Full Text] [Related]
10. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancer.
Ilelis F; do Amaral NS; Alves MR; da Costa AABA; Calsavara VF; Lordello L; De Brot L; Soares FA; Rodrigues IS; Rocha RM
Pathol Res Pract; 2018 Feb; 214(2):187-194. PubMed ID: 29254797
[TBL] [Abstract][Full Text] [Related]
12. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
13. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
